Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Prognostic significance of bleeding definitions in clinical investigations of oral anticoagulants
EF 2021-22
Résumé
Anticoagulants, or blood-thinners, are used to treat a variety of conditions such as a clot in the limbs or lungs. They are also used to prevent clot formation in high-risk individuals, such as in those with certain heart rhythm conditions (known as atrial fibrillation) or following knee or hip surgeries. The most common complication associated with anticoagulant use is bleeding. Therefore, understanding the risks and consequences of bleeding is key to facilitate shared decision-making with patients when starting anticoagulants. While there are robust data on the impact of major bleeding on survival and quality of life, there is lack of knowledge on the consequences of a lesser-known entity called clinically relevant non-major bleeding. Clinically relevant non-major bleeding is defined as a bleed that does not lead to death, significant blood loss or transfusion, but nonetheless requiring an unscheduled assessment by a healthcare professional. Despite occurring three times more often than major bleeding and affecting 10-15 per cent of anticoagulant-treated patients, the consequences of clinically relevant non-major bleeds are under-appreciated and understudied. We aim to understand the clinical impact of non-major bleeding events associated with oral anticoagulants, and how such bleeds influence the decision of patients and providers to continue or stop anticoagulant treatment. By looking at the outcomes of patients suffering from blood thinner complications using real-world patient data, we hope to provide information about the clinical trajectory of patients who suffer this common complication and to improve the safety of blood, all aimed at enhancing the health and well-being of patients undergoing blood-thinner treatment.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
467079
Name
Xu Yan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Prognostic significance of bleeding definitions in clinical investigations of oral anticoagulants
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adverse Events; Anticoagulation; Atrial Fibrillation; Hemostasis; Pharmacoepidemiology; Venous Thromboembolism
Abstract
Anticoagulants, or blood-thinners, are used to treat a variety of conditions such as a clot in the limbs or lungs. They are also used to prevent clot formation in high-risk individuals, such as in those with certain heart rhythm conditions (known as atrial fibrillation) or following knee or hip surgeries. The most common complication associated with anticoagulant use is bleeding. Therefore, understanding the risks and consequences of bleeding is key to facilitate shared decision-making with patients when starting anticoagulants. While there are robust data on the impact of major bleeding on survival and quality of life, there is lack of knowledge on the consequences of a lesser-known entity called clinically relevant non-major bleeding. Clinically relevant non-major bleeding is defined as a bleed that does not lead to death, significant blood loss or transfusion, but nonetheless requiring an unscheduled assessment by a healthcare professional. Despite occurring three times more often than major bleeding and affecting 10-15 per cent of anticoagulant-treated patients, the consequences of clinically relevant non-major bleeds are under-appreciated and understudied. We aim to understand the clinical impact of non-major bleeding events associated with oral anticoagulants, and how such bleeds influence the decision of patients and providers to continue or stop anticoagulant treatment. By looking at the outcomes of patients suffering from blood thinner complications using real-world patient data, we hope to provide information about the clinical trajectory of patients who suffer this common complication and to improve the safety of blood, all aimed at enhancing the health and well-being of patients undergoing blood-thinner treatment.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Xu, Yan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~